|
Trachte, George J (2003) Natriuretic peptides suppress protein kinase C activity to reduce evoked dopamine efflux from pheochromocytoma (PC12) cells. Endocrinology 144:94-100
|
|
Trachte, G J (2000) Depletion of natriuretic peptide C receptors eliminates inhibitory effects of C-type natriuretic peptide on evoked neurotransmitter efflux. J Pharmacol Exp Ther 294:210-5
|
|
Kanwal, S; Lowe, D G; Trachte, G J (1999) Intracellular fragments of the natriuretic peptide receptor-C (NPR-C) attenuate dopamine efflux. Endocrinology 140:1118-24
|
|
Kanwal, S; Elmquist, B J; Trachte, G J (1997) Atrial natriuretic peptide inhibits evoked catecholamine release by altering sensitivity to calcium. J Pharmacol Exp Ther 283:426-33
|
|
Trachte, G J; Kanwal, S; Elmquist, B J et al. (1995) C-type natriuretic peptide neuromodulates via ""clearance"" receptors. Am J Physiol 268:C978-84
|
|
Trachte, G J; Drewett, J G (1994) C-type natriuretic peptide neuromodulates independently of guanylyl cyclase activation. Hypertension 23:38-43
|
|
Trachte, G J (1993) Atrial natriuretic factor alters neurotransmission independently of guanylate cyclase-coupled receptors in the rabbit vas deferens. J Pharmacol Exp Ther 264:1227-33
|
|
Anand-Srivastava, M B; Trachte, G J (1993) Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol Rev 45:455-97
|
|
Drewett, J G; Ziegler, R J; Trachte, G J (1992) Neuromodulatory effects of atrial natriuretic peptides correlate with an inhibition of adenylate cyclase but not an activation of guanylate cyclase. J Pharmacol Exp Ther 260:689-96
|
